Could Oral Paclitaxel Plus Encequidar Be Offered as Outpatient mBC Treatment?

April 5, 2021

Gerardo Umanzor, MD, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 pandemic.

Gerardo Umanzor, MD, medical oncologist with Centro Oncologico Integral in San Pedro Sula, Honduras, explains the potential benefits of oral paclitaxel and encequidar compared with the intravenous (IV) formulation for the treatment of metastatic breast cancer during the coronavirus disease 2019 (COVID-19) pandemic.

In the phase 3 KX-ORAX-001 clinical trial (NCT02594371), progression-free survival (PFS) and overall survival (OS) improvement were achieved with the combination of oral paclitaxel plus encequidar versus intravenous paclitaxel plus encequidar. Umanzor says that considering the limitations of access to care during the pandemic, the idea of an outpatient treatment option is appealing for both physicians and patients.

A shift from IV infusions may also be a more cost-effective strategy for treating patients explains Umanzor, because inpatient care tends to be more costly compared with outpatient care.